MinervaX announces that it today has dosed the first subject in it Phase I Part B Dose-confirmation trial on its Group B Streptococcal vaccine GBS-NN, due to enrol 240 healthy adult women.
- MinervaX announces that EMA has awarded PRIME Status for its Group B Streptococcal vaccine 20/09/2022
- MinervaX Provides Clinical Update on its Maternal GBS Vaccine 14/02/2022
- MVX0004 Phase II 11/02/2022
- MinervaX provides clinical and leadership update 07/10/2021
- MVX0003 Phase I 01/02/2021